Havana, May 10 (RHC)-- More than 65,000 Cubans have benefited from the use of Heberprot-P, almost 10 years after the medication was first introduced into the national healthcare system to treat foot ulcers –-a common complication in diabetic patients.

Developed by a team of researchers at the Havana-based Center for Genetic Engineering and Biotechnology (CIGB), the medication –the only one of its kind in the world-- has been proven to significantly reduce the risk of amputation in almost 80% of cases.

Registered in over 20 nations, Heberprot-P was granted the Gold Medal from the World Intellectual Property Organization. Nearly 250,000 patients have benefited from its use worldwide. 

Havana’s Riviera Hotel will host the 19th National Meeting on the Use of Heberprot-P in the Treatment of Patients with Diabetic Foot Ulcers. 
Organized by the Ministry of Public Health in collaboration with the Center for Genetic Engineering and Biotechnology, the event will take place May 11th and 12th, and will gather more than 250 experts and vascular surgeons. The aim is to review the program's results thus far, as well as the treatment's expansion to benefit more patients around the globe.